Role of Novel Oral Anticoagulants in Primary and Secondary Thromboprophylaxis in Cancer

This article is intended to deliver a clinically relevant overview about the role of coagulation factors and platelets in the pathogenesis of pulmonary hypertension. After summarizing the available data with warfarin, some information is provided about the novel oral anticoagulants that were recently approved for atrial fibrillation and may soon be approved for venous thrombosis. The author is hopeful that this information will stimulate investigator interest in this topic and drive us toward meaningful studies about this important aspect of PAH therapy.

Download Full-text

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?

Thrombosis ◽

10.1155/2012/758385 ◽

2012 ◽

Vol 2012 ◽

pp. 1-9 ◽

Cited By ~ 9

Author(s):

Ludmila Katherine Martin ◽

Tanios Bekaii-Saab

Keyword(s):

Venous Thromboembolism ◽

Gastrointestinal Cancer ◽

Vitamin K Antagonists ◽

Dabigatran Etexilate ◽

Oral Anticoagulants ◽

Safety Data ◽

Novel Oral Anticoagulants ◽

Gastrointestinal Cancers ◽

Frequent Monitoring

Venous thromboembolism (VTE) is a frequent complication of gastrointestinal cancers that increases morbidity and may impact mortality. Low-molecular-weight heparins (LMWHs) and vitamin K antagonists (VKAs) are standard anticoagulation options for the ambulatory gastrointestinal cancer patient with VTE, but both of these agents are challenging to use for various reasons. Novel oral anticoagulants (NOAs) are new, orally available anticoagulants designed to be easier to administer with more reliable pharmacokinetics that eliminate the need for frequent monitoring of various laboratory parameters. This paper reviews the existing efficacy and safety data for the use of NOAs dabigatran etexilate, rivaroxaban, and apixaban and discusses the potential role of these agents in the management of gastrointestinal cancer-related VTE.

Download Full-text

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants

Medicina ◽

10.3390/medicina55100617 ◽

2019 ◽

Vol 55 (10) ◽

pp. 617 ◽

Cited By ~ 1

Author(s):

Caturano ◽

Galiero ◽

Pafundi

Keyword(s):

Atrial Fibrillation ◽

Vitamin K ◽

Stroke Risk ◽

Vitamin K Antagonists ◽

Oral Anticoagulants ◽

Life Quality ◽

Novel Oral Anticoagulants ◽

New Findings ◽

Ischemic Stroke Risk

Atrial fibrillation (AF) is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. One important issue is represented by the 5-fold increased ischemic stroke risk in AF patients. Hence, the role of anticoagulation is central. Until a few years ago, vitamin K antagonists (VKAs) and low molecular weight heparin represented the only option to prevent thromboembolisms, though with risks. Novel oral anticoagulants (NOACs) have radically changed the management of AF patients, improving both life expectancy and life quality. This review aims to summarize the most recent literature on the use of VKAs and NOACs in AF, in light of the new findings.

Download Full-text